Approximately 40% of HR+/HER2- breast cancers have activating mutations in the PIK3CA gene, leading to the hyperactivation of the catalytic subunit p110α of phosphatidylinositol 3-kinase (PI3K). The gene discussed is ERBB2; the disease is breast cancer.